002332 Zhejiang Xianju Pharmaceutical
- 11.55
- -0.10-0.86%
Zhejiang Xianju Pharmaceutical News
Should Income Investors Look At Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) Before Its Ex-Dividend?
It looks like Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) is about to go ex-dividend in the next two days. The ex-dividend date is one business day before a company's record date, which is
Zhejiang Xianju PharmaceuticalLtd's (SZSE:002332) 16% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns.
Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) Soars 25% But It's A Story Of Risk Vs Reward
Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) shareholders would be excited to see that the share price has had a great month, posting a 25% gain and recovering from prior weakness. Not all
Xianju Pharmaceutical (002332.SZ): Net profit of 151 million yuan in the first quarter increased 13.53% year-on-year
Gelonghui, April 24, 丨 Xianju Pharmaceutical (002332.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,038 million yuan, up 8.42% year on year; net profit attributable to shareholders of listed companies was 151 million yuan, up 13.53% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 145 million yuan, up 9.83% year on year; basic earnings per share were 0.15 yuan.
Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Zhejiang Xianju PharmaceuticalLtd's (SZSE:002332) recent performance, when its stock has declined 11% over the past three months. But if you pay close atte
A Look At The Intrinsic Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Zhejiang Xianju PharmaceuticalLtd fair value estimate is CN¥9.79 With CN¥9.46 share price, Zhejiang Xianju PharmaceuticalLtd appears to be tr
Xianju Pharmaceutical (002332.SZ): Plans to relinquish the priority subscription rights for Cuize Pharmaceutical's current capital increase
Gelonghui on March 7 丨 Xianju Pharmaceutical (002332.SZ) announced that Zhejiang Cuize Pharmaceutical Technology Co., Ltd. (“Cuize Pharmaceutical”) is a shareholding company of Zhejiang Xianju Pharmaceutical Co., Ltd., and the company holds 41.6501% of its shares. Recently, the company received a notice that Cuize Pharmaceutical plans to introduce investors to increase its registered capital. The registered capital is to be increased from 137.255.24 million yuan to 15.7019.53 million yuan, and the registered capital is 19.76.429 million yuan. The capital increase price is 36.43 yuan/share. Based on actual business conditions, the company plans to give up the priority of Cuize Pharmaceutical's current capital increase
Xianju Pharmaceutical (002332.SZ): Progesterone gel has recommunicated the clinical plan and is in the clinical preparation stage
Gelonghui Feb. 29丨An investor asked Xianju Pharmaceutical (002332.SZ) on the investor interactive platform, “Have the relevant application materials for the new flavonoid sustained-release gel been completed and submitted?” The company replied that progesterone gel has recommunicated the clinical plan and is in the clinical preparation stage.
Xianju Pharmaceutical (002332.SZ): Application for registration of estradiol tablets accepted
Gelonghui, Feb. 21丨Xianju Pharmaceutical (002332.SZ) announced that the company recently received a notice of acceptance of the registration of drugs produced domestically produced in estradiol tablets issued by the State Drug Administration. Estradiol tablets, the specification is 1 mg. The reference preparation is estradiol tablets marketed in the US (trade name: ESTRADIOL). The reference formulation for estradiol tablets was developed by BARR LABORATORIESINC and approved for marketing by the US FDA on October 22, 1997. Estradiol tablets are indicated for diseases related to estrogen deficiency, and can also prevent osteoporosis.
Xianju Pharmaceutical (002332.SZ): Received a notice of acceptance of the consistency evaluation of vecuronium bromide for injection
Gelonghui, Feb. 19: Xianju Pharmaceutical (002332.SZ) announced that the company recently received a notice of acceptance of the consistency evaluation of vecuronium bromide for injection issued by the State Drug Administration. Vecuronium bromide for injection is a sterile freeze-dried powder needle. It is indicated as an adjuvant to general anesthesia. It is used for tracheal intubation during general anesthesia and muscle relaxation during surgery.
Xianju Pharmaceutical (002332.SZ): Medroxyprogesterone acetate raw material passed WHO PQ certification
Gelonghui, Feb. 7: Xianju Pharmaceutical (002332.SZ) announced that recently, Zhejiang Xianju Pharmaceutical Co., Ltd. received a CPQ (Confirmation of WHO Active Pharmaceutical Precertification Prequalification, a pre-certification confirmation letter, hereinafter referred to as the CPQ certificate) issued by the World Health Organization (“WHO”) for sterile raw materials of medroxyprogesterone acetate. Medroxyprogesterone acetate is a progestogen-like drug. The indications are contraception, treatment of endometriosis, and treatment
Little Excitement Around Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Earnings As Shares Take 27% Pounding
Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. Instead of being r
The Total Return for Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) shareholders have seen the share price descend 13% over the month. Looking further back, the stock has generated good profits over five years.
Xianju Pharmaceutical (002332.SZ) has been re-certified as a high-tech enterprise
Gelonghui, January 11 | Xianju Pharmaceutical (002332.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Zhejiang Provincial Department of Science and Technology, the Zhejiang Provincial Department of Finance, and the Zhejiang Provincial Taxation Bureau of the State Administration of Taxation.
Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Stock Has Fared Decently: Is the Market Following Strong Financials?
Zhejiang Xianju PharmaceuticalLtd's (SZSE:002332) stock is up by 9.5% over the past three months. Since the market usually pay for a company's long-term financial health, we decided to study the com
Xianju Pharma to Invest 33 Million Yuan in Local Drug R&D Firm
Zhejiang Xianju Pharmaceutical (SHE:002332) plans to take part in the capital increase of a local innovative drug research and development company by investing 33.1 million yuan for a 5.13% stake. The
Xianju Pharmaceutical (002332.SZ): Plans to invest 40 million yuan to participate in Yuhong Pharmaceutical
On December 26, Gelonghui Pharmaceutical (002332.SZ) announced that Hangzhou Yuhong Pharmaceutical Technology Co., Ltd. (“Yuhong Pharmaceutical”) is engaged in innovative drug research and development and industrialization related businesses. It currently has a registered capital of 5.8 million yuan and plans to increase the registered capital of 6628.57 million yuan. Zhejiang Xianju Pharmaceutical Co., Ltd. plans to invest in Yuhong Pharmaceutical and will use its own capital of RMB 40 million to pledge Yuhong Pharmaceutical's additional registered capital of RMB 3314.29 million. After this investment, the company will hold 5.1282% of Yuhong Pharmaceutical's shares.
Is Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) Worth CN¥12.1 Based On Its Intrinsic Value?
Key Insights Zhejiang Xianju PharmaceuticalLtd's estimated fair value is CN¥9.09 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥12.11 suggests Zhejiang Xianju PharmaceuticalLtd
Xianju Pharmaceutical (002332.SZ): Flumazenil injection plans to be selected for the ninth batch of national drug collection
Gelonghui November 7 - Xianju Pharmaceutical (002332.SZ) announced that on November 6, 2023, the company participated in the bidding process for the ninth batch of centralized national drug procurement organized by the Joint Drug Procurement Office of the State Organization. The company's product, flumazenil injection, is to be selected for this centralized procurement.
Xianju Pharmaceutical (002332.SZ): The registration application for didrogesterone tablets was accepted
Gelonghui November 2 - Xianju Pharmaceutical (002332.SZ) announced that the company recently received a notice of acceptance of drug registration for domestic production of didrogesterone tablets issued by the State Drug Administration. The size of didrogesterone tablets is 10mg. The reference preparation is didrogesterone tablets imported from the original research. Brand name: Duphaston (Duphaston). This reference formulation was developed by Abbott Healthcare Products B.V in the Netherlands, marketed in the Netherlands in 1968 in May 1968, and Dafton? Approved for import in China. Indications for use of dydrogesterone tablets
Analysis
Price Target
No Data
